Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer

Abstract We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan–Meier estimator and log-rank...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ki-Tae Hwang, Young A. Kim, Jongjin Kim, Hyeon Jeong Oh, Jeong Hwan Park, In Sil Choi, Jin Hyun Park, Sohee Oh, Ajung Chu, Jong Yoon Lee, Kyu Ri Hwang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6e6c0c07e100449a88683517d9851ddc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e6c0c07e100449a88683517d9851ddc
record_format	dspace
spelling	oai:doaj.org-article:6e6c0c07e100449a88683517d9851ddc2021-12-02T17:30:53ZPrognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer10.1038/s41598-021-90506-x2045-2322https://doaj.org/article/6e6c0c07e100449a88683517d9851ddc2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90506-xhttps://doaj.org/toc/2045-2322Abstract We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan–Meier estimator and log-rank test were used for survival analyses. The Cox proportional hazards model was used to calculate hazard ratio (HR) and the 95% confidence interval (CI) of survival analyses. BCL1 expression revealed no impact on survival. The high BCL2 group showed superior disease-free survival compared with the low BCL2 group (p = 0.002), especially regarding local recurrence-free survival (p = 0.045) and systemic recurrence-free survival (p = 0.002). BCL2 expression was a significant prognostic factor by univariable analysis (HR, 0.528; 95% CI, 0.353–0.790; p = 0.002) and by multivariable analysis (HR, 0.547; 95% CI, 0.362–0.826; p = 0.004). High BCL2 expression was associated with higher disease-free survival in the hormone receptor (HRc)-positive and human epidermal growth factor receptor 2 (HER2)-negative (HRc(+)/HER2(−)) subtype only (p = 0.002). The high BCL2 group was associated with positive estrogen receptor (ER), positive progesterone receptor (PR), low histologic grade, and age ≤ 50 years. BCL1 expression had no prognostic impact, but BCL2 expression was a significant independent prognostic factor. High BCL2 expression was associated with higher disease-free survival, especially regarding local recurrence and systemic recurrence. The prognostic effect of BCL2 expression was effective only in the HRc(+)/HER2(−) subtype. Favorable clinicopathologic features and a strong association with the ER/PR status could partly explain the superior prognosis of the high BCL2 group. BCL2 expression could be utilized to assess the prognosis of breast cancer patients in clinical settings.Ki-Tae HwangYoung A. KimJongjin KimHyeon Jeong OhJeong Hwan ParkIn Sil ChoiJin Hyun ParkSohee OhAjung ChuJong Yoon LeeKyu Ri HwangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ki-Tae Hwang Young A. Kim Jongjin Kim Hyeon Jeong Oh Jeong Hwan Park In Sil Choi Jin Hyun Park Sohee Oh Ajung Chu Jong Yoon Lee Kyu Ri Hwang Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
description	Abstract We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan–Meier estimator and log-rank test were used for survival analyses. The Cox proportional hazards model was used to calculate hazard ratio (HR) and the 95% confidence interval (CI) of survival analyses. BCL1 expression revealed no impact on survival. The high BCL2 group showed superior disease-free survival compared with the low BCL2 group (p = 0.002), especially regarding local recurrence-free survival (p = 0.045) and systemic recurrence-free survival (p = 0.002). BCL2 expression was a significant prognostic factor by univariable analysis (HR, 0.528; 95% CI, 0.353–0.790; p = 0.002) and by multivariable analysis (HR, 0.547; 95% CI, 0.362–0.826; p = 0.004). High BCL2 expression was associated with higher disease-free survival in the hormone receptor (HRc)-positive and human epidermal growth factor receptor 2 (HER2)-negative (HRc(+)/HER2(−)) subtype only (p = 0.002). The high BCL2 group was associated with positive estrogen receptor (ER), positive progesterone receptor (PR), low histologic grade, and age ≤ 50 years. BCL1 expression had no prognostic impact, but BCL2 expression was a significant independent prognostic factor. High BCL2 expression was associated with higher disease-free survival, especially regarding local recurrence and systemic recurrence. The prognostic effect of BCL2 expression was effective only in the HRc(+)/HER2(−) subtype. Favorable clinicopathologic features and a strong association with the ER/PR status could partly explain the superior prognosis of the high BCL2 group. BCL2 expression could be utilized to assess the prognosis of breast cancer patients in clinical settings.
format	article
author	Ki-Tae Hwang Young A. Kim Jongjin Kim Hyeon Jeong Oh Jeong Hwan Park In Sil Choi Jin Hyun Park Sohee Oh Ajung Chu Jong Yoon Lee Kyu Ri Hwang
author_facet	Ki-Tae Hwang Young A. Kim Jongjin Kim Hyeon Jeong Oh Jeong Hwan Park In Sil Choi Jin Hyun Park Sohee Oh Ajung Chu Jong Yoon Lee Kyu Ri Hwang
author_sort	Ki-Tae Hwang
title	Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
title_short	Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
title_full	Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
title_fullStr	Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
title_full_unstemmed	Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
title_sort	prognostic influences of bcl1 and bcl2 expression on disease-free survival in breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6e6c0c07e100449a88683517d9851ddc
work_keys_str_mv	AT kitaehwang prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT youngakim prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT jongjinkim prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT hyeonjeongoh prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT jeonghwanpark prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT insilchoi prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT jinhyunpark prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT soheeoh prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT ajungchu prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT jongyoonlee prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT kyurihwang prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer
_version_	1718380732940812288

Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer

Ejemplares similares